TNF Superfamily Member 14 Drives Post-Influenza Depletion of Alveolar Macrophages Enabling Secondary Pneumococcal Pneumonia.

Summary

Using single-cell transcriptomics and in vivo IAV and IAV/Spn co-infection models, the study identifies the TNFSF14 ligand-receptor axis as the driver of early post-influenza death of tissue-resident alveolar macrophages. Neutralizing components of this pathway and transferring genetically modified TR-AMs mitigated disease, and TNFSF14 was abundant in BALF from severe virus-induced ARDS patients.

Key Findings

• Day-7 post-IAV, tissue-resident alveolar macrophages were markedly depleted, correlating with increased susceptibility to pneumococcal outgrowth.
• Unbiased single-cell and cell-specific profiling identified the TNFSF14 axis as the driver of TR-AM death; antibody neutralization and transfer of genetically modified TR-AMs alleviated disease.
• TNFSF14 was mainly expressed by neutrophils and highly abundant in BALF of patients with severe virus-induced ARDS, supporting translational relevance.

Clinical Implications

TNFSF14 could serve as a biomarker and therapeutic target to prevent secondary pneumococcal pneumonia and mitigate virus-induced ARDS severity. Early-phase trials of pathway blockade merit consideration.

Limitations

• Primarily preclinical; human data limited to BALF biomarker observation
• Intervention timing/dosing and species differences may limit direct clinical translation

Future Directions

Evaluate TNFSF14 blockade in larger animal models and design phase I/II trials in high-risk viral pneumonia/ARDS to prevent secondary bacterial pneumonia.